Topiramate in the Treatment of Substance-Related Disorders: A Critical Review of the Literature
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To critically review the literature on topiramate in the treatment of substance-related disorders. DATA SOURCES: A PubMed search of human studies published in English through January 2009 was conducted using the following search terms: topiramate and substance abuse, topiramate and substance dependence, topiramate and withdrawal, topiramate and alcohol, topiramate and nicotine, topiramate and cocaine, topiramate and opiates, and topiramate and benzodiazepines. STUDY SELECTION: 26 articles were identified and reviewed; these studies examined topiramate in disorders related to alcohol, nicotine, cocaine, methamphetamine, opioids, Ecstasy, and benzodiazepines. DATA EXTRACTION: Study design, sample size, topiramate dose and duration, and study outcomes were reviewed. DATA SYNTHESIS: There is compelling evidence for the efficacy of topiramate in the treatment of alcohol dependence. Two trials show trends for topiramate's superiority over oral naltrexone in alcohol dependence, while 1 trial suggests topiramate is inferior to disulfiram. Despite suggestive animal models, evidence for topiramate in treating alcohol withdrawal in humans is slim. Studies of topiramate in nicotine dependence show mixed results. Human laboratory studies that used acute topiramate dosing show that topiramate actually enhances the pleasurable effects of both nicotine and methamphetamine. Evidence for topiramate in the treatment of cocaine dependence is promising, but limited by small sample size. The data on opioids, benzodiazepines, and Ecstasy are sparse. CONCLUSIONS: Topiramate is efficacious for the treatment of alcohol dependence, but side effects may limit widespread use. While topiramate's unique pharmacodynamic profile offers a promising theoretical rationale for use across multiple substance-related disorders, heterogeneity both across and within these disorders limits topiramate's broad applicability in treating substance-related disorders. Recommendations for future research include exploration of genetic variants for more targeted pharmacotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects
Astrup, A., Caterson, I., Zelissen, P., Guy‐Grand, B., Carruba, M., Levy, B., Sun, X., Fitchet, M., & OBES‐004 Study Group (2004) · Obesity Research · doi:10.1038/oby.2004.206 · Cited by 143
Topiramate selectively attenuates nicotine-induced increases in monoamine release
Schiffer, W. K., Gerasimov, M. R., Marsteller, D. A., Geiger, J., Barnett, C., Alexoff, D. L., & Dewey, S. L. (2001) · Synapse · doi:10.1002/syn.10000 · Cited by 69
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“Its use in substance use disorders including alcohol dependence has recently been reviewed (de Sousa, 2010; Johnson and Ait-Daoud, 2010; Shinn and Greenfield, 2010).”
BackgroundNeuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Anxiety and alcohol use disorders: comorbidity and treatment considerations
Smith, J. (2012) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v34.4.06 · Cited by 255
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“16 © 2013 The Authors British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society enhancing GABAergic tone [139].”
Background
Metadata
- Authors
- Shinn, A. K., & Greenfield, S. F.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-03-09
- Volume
- 71
- Issue
- 05
- Pages
- 634-648
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2083372110
- Cited by
- 103
- References
- 11
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.